China NT Pharma Group Co., Ltd.
HHKEX:10110.29
HKD
-0.03
(-9.52%)
ISIN
KYG2114L1133
CUSIP
G2114L113
Return %
Stock
S&P 500
1Y
-66.07
14.20
3Y
-96.44
81.12
5Y
-96.61
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Ching Kit Ng
- Full Time Employees
- 22
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- West Tower Hong Kong Hong Kong
- IPO Date
- Apr 20, 2011
- Website
- ntpharma.com
- Similar Companies
- Business
- China NT Pharma Group Company Limited (1011.HK), an investment holding company founded in 1995 and headquartered in Central, Hong Kong, engages in the research, development, manufacturing, sales, and distribution of pharmaceutical products primarily in the People's Republic of China. The company manufactures, sells, and trades prescription medicines targeting tumor and blood system diseases, digestive system diseases, central nervous system diseases, respiratory system diseases, and other therapeutic areas; produces and markets NT branded products and generic drugs; and offers marketing, promotion, logistics, and consulting services to pharmaceutical suppliers. It operates through digital services and sales agency segments, acting as an agent for medical and health-related products, with subsidiaries and operations spanning Shanghai, Beijing, Guangzhou, Suzhou, Taizhou, Hainan, and other locations across China, supported by three pharmaceutical factories for contract manufacturing and branded production. Historically a leading provider of vaccine supply chain, promotion, and sales services—once the largest comprehensive vaccine distributor in China covering over 79% of disease control centers—the company has shifted focus to digital healthcare, bone health platforms under the "福艾蒙" brand integrating drugs, devices, rehabilitation, and digital medical services, and orthopedic markets with AI-powered bone density analysis systems and orthopedic drugs. Recent developments include the 2020 establishment of Beijing Kangchen Biotechnology Co., Ltd., a joint venture with Kangchen Pharmaceutical invested at RMB 900 million, focusing on the "密盖息" brand for bone health services with OEM factories in Germany and France, over 150 employees, and annual sales exceeding RMB 300 million; acquisition of commercial rights to global top-10 new drug olitumomab (奥替单抗) in Greater China plus Southeast Asia, advancing to U.S. Phase II trials; and clarification of financial figures in a major acquisition announced in 2025, alongside a strategic pivot to digital services businesses. The group maintains partnerships with multinational firms such as GlaxoSmithKline, Pfizer, Sanofi-Pasteur, and Novartis, serving nationwide medical networks, grassroots institutions, and international markets through its integrated supply chain capabilities.